Chemotherapy and QT prolongation: Overview with clinical perspective

Current Treatment Options in Cardiovascular Medicine

Volumn 16, Issue 5, 2014, Pages

  Kim, Peter Y ^a   Ewer, Michael S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cardiac monitoring; Cardiotoxicity; Chemotherapy; QT prolongation; Torsades de pointes

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMPHETAMINE; ANAGRELIDE; ARSENIC TRIOXIDE; ATAZANAVIR; AZITHROMYCIN; CIPROFLOXACIN; CITALOPRAM; DASATINIB; DEPSIPEPTIDE; DIPHENHYDRAMINE; FAMOTIDINE; FLUCONAZOLE; GEMIFLOXACIN; HALOPERIDOL; KETOCONAZOLE; LAPATINIB; METHADONE; NILOTINIB; SALBUTAMOL; SUNITINIB; TRAZODONE; VANDETANIB; VEMURAFENIB; VORINOSTAT;

ARTICLE; CANCER PATIENT; CANCER THERAPY; CARDIOLOGIST; CHEMOTHERAPY; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; HEART RATE; HEART VENTRICLE CONDUCTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; ONCOLOGIST; PATHOPHYSIOLOGY; POLYPHARMACY; QT INTERVAL; QT PROLONGATION; RECOGNITION; RISK FACTOR; SUDDEN CARDIAC DEATH; TORSADE DES POINTES;

EID: 84898825699     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-014-0303-8     Document Type: Article

References (43)

1. Grant A. Cardiac ion channels. Circ Arrhythm Electrophysiol. 2009;2(2):185-94.
2. Meissner FL. Taubstummheit und Taubstummenbildung: Beobachtungen und Erfahrungen. Winter'sche Verlagshandlung (Leipzig) 1856;119-20.
3. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur. 1966;59:263-72.
4. Translated in Cardiovasc Drugs Ther 1990;4:1171-6.
5. •• Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings. Sci Statement Am Heart Assoc Am Coll Cardiol Found JACC. 2010;55(9):934-47. The ACC/AHA statement outlines the importance of cardiac monitoring for QT prolongation and torsade de pointes. It provides a comprehensive review and current recommendations for assessment of hospitalized patients.
6. Rampe D, Brown AM. A history of the role of the hERG channel in cardiac risk assessment. J Pharmacol Toxicol Methods. 2013;68:13-22.
7. Xue J, Gao W, et al. Identify drug-induced T wave morphology changes by a cell-to-electrocardiogram model and validation with clinical trial data. J Electrocardiol. 2009;42:534-42.
8. •• Postema PG, De Jong J, Van der Bilt I, et al. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm. 2008;5:1015-8. This paper describes the proper technique in measuring the QT interval to ensure consistent and accurate interpretation.
9. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram : part I: the electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology. Circulation. 2007;115:1306-24. (Pubitemid 46594775)
10. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2:569-74. (Pubitemid 40724120)
11. Riera AR, Ferreira C, Filho CF, et al. The enigmatic sixth wave of the electrocardiogram: The U wave. Cardiol J. 2008;15:408-21.
12. Rautaharju PM, Zhang ZM, Prineas R, et al. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol. 2004;93:1017-21. (Pubitemid 38479457)
13. Luo S, Michler K, Johnston P, et al. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol. 2004;37(Suppl):81-90. (Pubitemid 39452873)
14. • International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; Food and Drug Administration, HHS. Fed Regist. 2005;70(202):61134-5. The FDA guidelines on clinical evaluation of medications lists recommended practices in safely evaluating medication effects on cardiac repolarization.
15. Gallagher MM, Magliano G, Yap YG, et al. Distribution and prognostic significance of QT intervals in the lowest half centile in 12,012 apparently healthy persons. Am J Cardiol. 2006;98(7):933-5. (Pubitemid 44402263)
16. Funada A, Hayashi K, Ino H, et al. Assessment of QT intervals and prevalence of short QT syndrome in Japan. Clin Cardiol. 2008;31(6):270-4. (Pubitemid 351961238)
17. Kobza R, Roos M, Niggli B, et al. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart Rhythm. 2009;6:652-7.
18. Varterasian M, Meyer M, Fingert H, et al. Baseline heart rate-corrected QT and elgibility for clinical trials in oncology. J Clin Oncol. 2003;99(104):3378-9.
19. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of Imatinib. Clin Cancer Res. 2008;14:5325-31.
20. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852-60. (Pubitemid 32880064)
21. Arsenic trioxide (Trisenox). Package Insert. Seattle, WA: Cell Therapeutics, Inc.
22. Vemurafenib (Zelboraf). Package Insert. San Francisco, CA: Genentech USA, Inc.
23. Depsipeptide (Istodax). Package Insert. Summit, NJ: Celgene Corporation.
24. Vorinostat (Zolinza). Package Insert. Mississauga, Ontario, Canada: Patheon, Inc.
25. Dasatanib (Spyrcel). Package Insert. Princeton, NJ: Bristo-Myers Squibb Company.
26. Johnson F, Agrawal S, Burris H, et al. Phase 1 Pharmacokinetic and drug-interaction study in Dasatinib in patients with advanced solid tumors. Cancer. 2010;116:1582-91.
27. Lapatinib (Tykerb). Package Insert. Research Triangle Park, NJ: GlaxoSmithKline.
28. Burris H, Taylor C, Jones S, et al. A phase I and pharmacokinetic study of oral Lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009;15(21):6702-8.
29. Nilotinib (Tasigna). Package Insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
30. Deremer D, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30:1956-75.
31. Sunitinib (Sutent). Package Insert. New York City, NY: Pfizer Inc.
32. Bello C, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of Sunitinib. Clin Cancer Res. 2009;15:7045-52.
33. Vandetanib (Caprelsa). Package Insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
34. Westervelt P, Brown RA, Adkins DR, et al. Blood. 2001;98(2):266-71.
35. Kumazaki M, Ando H, Kakei M, et al. a-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs. Eur J Pharmacol. 2013;705(1-3):1-10.
36. White P, Song D, Abrao J, et al. Effect of low-dose Droperidol on the QT interval during and after General Anesthesia. Anesthesiology. 2005;102:1101-5. (Pubitemid 40745826)
37. Estrada C, Prasad N, Rosman H, et al. Outcomes of patients hospitalized to a telemetry unit. Am J Cardiol. 1994;74:357-62. (Pubitemid 24253473)
38. Naing A, Veasey-Rodrigues H, Hong D, et al. Electrocardiograms in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012;23(11):2960-3.
39. ACC/AHA/ESC. guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48(5):e24-346.
40. Choy A, Lang C, Chomsky D, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149-54. (Pubitemid 27425816)
41. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1998;77:392-7.
42. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J. 1993;14(Suppl H):88-92. (Pubitemid 23352280)
43. ACC/AHA/HRS. guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation. 2008;117:e350-408.